Your browser doesn't support javascript.
loading
Development and characterization of a bacteriophage cocktail with high lytic efficacy against field-isolated Salmonella enterica.
Aguilera, Matías; Tobar-Calfucoy, Eduardo; Rojas-Martínez, Victoria; Norambuena, Rodrigo; Serrano, María Jesús; Cifuentes, Onix; Zamudio, María Sofía; San Martín, Daniel; Lara, Pabla; Sabag, Andrea; Zabner, Marcela; Tichy, Daniel; Camejo, Pamela; León, Luis; Pino, Michael; Ulloa, Soledad; Rojas, Felipe; Pieringer, Christian; Muster, Cecilia; Castillo, Daniel; Ferreira, Nicolás; Avendaño, Camilo; Canaval, Mauro; Pieringer, Hans; Cifuentes, Pablo; Cifuentes Muñoz, Nicolás.
Afiliação
  • Aguilera M; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Tobar-Calfucoy E; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Rojas-Martínez V; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Norambuena R; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Serrano MJ; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Cifuentes O; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Zamudio MS; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • San Martín D; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Lara P; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Sabag A; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Zabner M; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Tichy D; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Camejo P; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • León L; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Pino M; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Ulloa S; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Rojas F; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Pieringer C; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Muster C; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Castillo D; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Ferreira N; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Avendaño C; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Canaval M; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Pieringer H; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Cifuentes P; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.
  • Cifuentes Muñoz N; PhageLab Chile SpA, Vicuña Mackenna 4860, Centro de Innovación Anacleto Angelini 5th floor, Santiago, Chile.. Electronic address: ncifuentes@pht.cl.
Poult Sci ; 102(12): 103125, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37879168
ABSTRACT
Salmonella spp. is a prevalent pathogen that causes great public health concern worldwide. Bacteriophage-based cocktails have arisen as an alternative to antibiotics to inhibit the growth of Salmonella. However, the bactericidal effect of bacteriophage cocktails in vivo largely differs from their observed effect in vitro. This is partly because in vitro developments of cocktails do not always consider the bacterial diversity nor the environmental conditions where bacteriophages will have to replicate. Here, we isolated and sequenced 47 bacteriophages that showed variable degrees of lytic activity against 258 Salmonella isolates from a commercial broiler company in Brazil. Three of these bacteriophages were characterized and selected to assemble a cocktail. In vitro quantitative assays determined the cocktail to be highly effective against multiple serovars of Salmonella, including Minnesota and Heidelberg. Remarkably, the in vitro lytic activity of the cocktail was retained or improved in conditions that more closely resembled the chicken gut, such as anaerobiosis, 42°C, and Salmonella mono-strain biofilms. Analysis of bacterial cross-resistance between the 3 bacteriophages composing the cocktail revealed limited or no generation of cross-resistance. Our results highlight the relevance of an optimized flux of work to develop bacteriophage cocktails against Salmonella with high lytic efficacy and strong potential to be applied in vivo in commercial broiler farms.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bacteriófagos / Salmonella enterica Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Bacteriófagos / Salmonella enterica Idioma: En Ano de publicação: 2023 Tipo de documento: Article